title: EAE: a model for immune intervention with synthetic peptides.
abstract: The cellular and molecular requirements for the autoimmune disease EAE are being defined in increasing detail through intense scrutiny of critical autoantigenic peptides, class II MHC molecules, and alpha beta TCRs involved in the disease process. This study has led to novel immunotherapeutic approaches, many of which are based on the administration of synthetic peptides. Since short peptides are understood to be the minimal antigenic units bound by MHC molecules for recognition by T cells, they are attractive experimental tools for finely modulating specific immune responses. It is clear that a large number of defined peptides can dramatically influence the course of EAE. Table IV lists a number of potential mechanisms which may mediate disease prevention. Increasing evidence supports the idea that prevention of autoimmune disease can result from MHC-blockade by peptides which competitively bind to class II molecules. However, for some peptides such as the perplexing partial agonist Ac1-11[4A], the mechanism by which these precisely defined units act is not yet fully understood. Numerous hurdles hinder immediate clinical application of peptide-based immunotherapy. Nevertheless, the knowledge gained by probing experimental autoimmunity with defined peptides promises to inspire original and practical approaches to treating human autoimmune disease.
authors.affiliation: Department of Microbiology and Immunology, Stanford University School of Medicine, California 94305.
authors.forename: D E
authors.initials: DE
authors.lastname: Smilek
authors.forename: A M
authors.initials: AM
authors.lastname: Gautam
authors.forename: C
authors.initials: C
authors.lastname: Pearson
authors.forename: L
authors.initials: L
authors.lastname: Steinman
authors.forename: H O
authors.initials: HO
authors.lastname: McDevitt
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000628:therapy*; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007167:Immunotherapy; D008969:Molecular Sequence Data; D004676:Myelin Basic Protein / Q000138:chemical synthesis / Q000276:immunology / Q000627:therapeutic use*; D010455:Peptides / Q000138:chemical synthesis / Q000627:therapeutic use; D011948:Receptors, Antigen, T-Cell / Q000276:immunology
chemical_list: D000949:Histocompatibility Antigens Class II; D004676:Myelin Basic Protein; D010455:Peptides; D011948:Receptors, Antigen, T-Cell